Login to Your Account

Oncothyreon in Stock Plunge on Stimuvax Phase III Miss

By Cormac Sheridan
Staff Writer

Wednesday, December 26, 2012
Oncothyreon Inc. lost more than half its value during early trading last Wednesday after partner Merck KgaA disclosed that its cancer vaccine, L-BLP25 (Stimuvax), failed to meet the primary endpoint of overall survival in a pivotal Phase III trial in non-small-cell lung cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription